Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
The CAR-T being used in this trial is JCAR017 is nearly identical to the JCAR014 that I received in Seattle and has done so well by me.
And there are now several experienced and convenient sites that offer the trial including one with my own doctor, Dr. Tom Kipps and his team at UCSD:
Contact: Krisma C Montalvo 858-246-0386 kcmontalvo@ucsd.edu
Contact: Kimberly Aguilar 858-534-5201 k1aguilar@ucsd.edu
Principal Investigator: Thomas J Kipps, MD, PhD
For more information and a list of all the sites across the USA, please visit: https://clinicaltrials.gov/ct2/show/NCT03331198
CAR-T therapy is a great choice for the right patient and as of now a clinical trial is the only way to get access.
Stay strong. We are all in this together.
Brian
Related posts